Semax

What Is Semax?

Semax is a synthetic seven-amino-acid peptide with the sequence:

Met-Glu-His-Phe-Pro-Gly-Pro

It was developed from part of the hormone:

ACTH — adrenocorticotropic hormone.

More specifically, Semax combines:

ACTH(4–7)

with:

Pro-Gly-Pro — PGP.

So Semax is often described scientifically as:

ACTH(4–7)-Pro-Gly-Pro

or an analogue of ACTH(4–10).

Semax was designed to retain neurological activity associated with ACTH fragments without functioning like full-length ACTH as an adrenal-stimulating hormone.

Over the years, researchers have investigated it in areas involving:

stroke + brain injury + memory + learning + BDNF + neurotrophic signaling + oxidative stress + inflammation.

Why Are Researchers Interested in Semax?

Semax has a more substantial scientific history than the average “nootropic peptide” sold online.

Research stretches back decades and includes:

• Laboratory experiments
• Animal studies
• Gene-expression studies
• Ischemic stroke models
• Some human clinical studies

The strongest scientific theme is probably:

neuroprotection.

Researchers have studied whether Semax can influence the brain’s response to:

reduced blood flow + oxygen deprivation + neuronal injury + inflammation.

That is why so much of the early human literature focused on ischemic stroke rather than healthy people simply trying to focus harder at work. 

Does Semax Come From ACTH?

Yes, but calling Semax “ACTH” would be misleading.

Full ACTH is a much larger peptide hormone produced by the pituitary gland.

One of its primary jobs is stimulating the adrenal glands to produce:

cortisol.

Semax contains only a small sequence based on the 4–7 region of ACTH, followed by Pro-Gly-Pro.

Its neurological research therefore does not mean it has the same endocrine effects as full ACTH.

It was specifically developed as a neuroactive analogue rather than conventional ACTH hormone replacement.

How Might Semax Work?

There probably isn’t one single mechanism.

Research has identified effects involving:

• BDNF
• TrkB
• NGF
• Other neurotrophins
• Gene expression
• Neuroinflammation
• Oxidative stress
• Brain-cell survival pathways

One of the best-supported preclinical mechanisms involves:

BDNF / TrkB signaling.

BDNF stands for:

Brain-Derived Neurotrophic Factor.

TrkB is one of its primary receptors.

This signaling system helps regulate:

neuronal survival + synaptic plasticity + learning + memory + adaptation after injury.

Semax has repeatedly affected this pathway in animal studies. 

What About BDNF?

This is probably the claim most associated with Semax online.

And unlike some peptide-marketing claims, there is genuine research behind it.

A 2006 rat study found that a single intranasal Semax exposure increased hippocampal:

BDNF protein levels approximately 1.4-fold

and:

TrkB phosphorylation approximately 1.6-fold.

Researchers also observed increases in BDNF- and TrkB-related messenger RNA. 

Another rat study found changes in BDNF and NGF gene expression in the hippocampus and frontal cortex after Semax administration. 

So:

Semax affecting BDNF biology is legitimate preclinical science.

But:

“Semax boosts BDNF in humans and therefore makes your brain better” is not established.

Most of the direct mechanistic BDNF evidence comes from animals or cell research.

What Is Neuroplasticity?

Neuroplasticity describes the nervous system’s ability to change in response to:

learning + experience + injury + environmental signals.

BDNF and TrkB are important contributors to that process.

Because Semax influences neurotrophic signaling in animal studies, it frequently appears in discussions involving:

• Neuroplasticity
• Brain adaptation
• Synapse function
• Learning
• Memory
• Recovery after neurological injury

Those are legitimate research topics.

But there isn’t evidence showing that Semax simply:

“rewires your brain”

or dramatically increases neuroplasticity in healthy humans.

What About Memory?

Semax has a substantial animal literature involving:

learning and memory.

For example, the same rat study that observed increased BDNF/TrkB signaling also found changes in conditioned avoidance learning. 

Other animal work has described improved learning under various experimental conditions.

So memory isn’t just a random marketing association.

However, the leap from:

improved performance in animal learning tasks

to:

significantly better memory in healthy humans

has not been firmly established.

What About Focus & Concentration?

This is probably how many people encounter Semax today.

It is commonly marketed as a:

nootropic peptide

for:

• Focus
• Attention
• Productivity
• Mental clarity
• Concentration

Those claims are partly extrapolated from Semax’s cognitive and neurological research.

But we do not have large modern controlled trials showing that healthy adults taking Semax experience major improvements in everyday attention or productivity.

So:

attention research → reasonable

proven focus enhancer → too strong.

What About ADHD?

Semax frequently appears in searches involving ADHD because of its reputation as a cognitive peptide.

But there is not strong clinical evidence establishing Semax as a treatment for:

ADHD or other attention-deficit disorders.

There are no large modern FDA-standard ADHD trials establishing efficacy comparable to approved stimulant or non-stimulant medications.

ADHD belongs in our search system because people research it.

It shouldn’t be described as a proven Semax indication.

What About Brain Fog?

Same distinction.

Brain fog may refer to:

• Mental fatigue
• Poor attention
• Memory difficulty
• Slowed thinking
• Difficulty finding words
• Reduced mental clarity

Semax’s neurological research makes it understandable why people explore it.

But “brain fog” has many possible causes and Semax has not been established as a treatment for it.

What About Stroke?

This is one of the most important Semax research areas.

An older controlled clinical study evaluated Semax as part of treatment for acute hemispheric ischemic stroke.

Thirty patients received Semax alongside intensive therapy and were compared with 80 control patients receiving conventional treatment.

Researchers reported faster recovery of certain neurological deficits, particularly motor function. 

Other Russian research explored possible anti-inflammatory and neuroprotective effects during acute ischemic stroke. 

So Semax does have genuine human stroke research.

But there are major limitations.

The studies are:

• Old
• Relatively small
• Primarily Russian
• Not replicated through large multinational modern stroke programs
• Not sufficient for FDA approval

And critically:

Semax is NOT an approved emergency treatment for stroke in the United States.

Anyone with symptoms of stroke requires immediate emergency evaluation.

Experimental peptide use should never delay proven stroke treatment.

How Might Semax Affect an Ischemic Brain?

Ischemia means tissue isn’t receiving enough blood and therefore not enough oxygen and nutrients.

In the brain, ischemia can trigger:

energy failure → oxidative stress → inflammation → excitotoxicity → neuronal injury.

Animal stroke models have shown Semax-related changes in neurotrophic signaling.

For example, in rats with experimental middle cerebral artery occlusion, Semax increased transcription of several neurotrophin-related genes, including:

BDNF + NGF + Trk receptors.

That provides a plausible biological explanation for why researchers became interested in Semax as a neuroprotective compound.

But preclinical mechanism isn’t the same as proven clinical stroke benefit.

Does Semax Grow New Brain Cells?

This is an internet oversimplification.

BDNF and neurotrophins participate in:

neuronal survival + synaptic plasticity + neurogenesis-related biology.

But showing that Semax changes neurotrophin expression does not mean it has been demonstrated to:

grow new brain tissue in humans.

That’s several scientific leaps beyond the evidence.

What About Brain Injury?

Because Semax has been studied in:

ischemia + hypoxia + neuronal stress + neuroprotection,

researchers and peptide users often extend interest into:

• Traumatic brain injury
• Concussion
• Brain recovery
• Post-stroke recovery

These are reasonable research topics.

But clinical evidence for Semax specifically in human traumatic brain injury or concussion remains insufficient to establish it as a treatment.

What About Hypoxia?

Hypoxia means reduced oxygen availability.

Semax has shown neuroprotective effects in experimental models involving:

oxygen deprivation and ischemic injury.

This is one of the major foundations of its neuroprotection reputation.

Again, most mechanistic work is preclinical.

There isn’t evidence supporting self-treatment with Semax for acute oxygen deprivation or neurological emergencies.

What About Neurodegenerative Diseases?

Semax’s effects on:

BDNF + oxidative stress + neuroinflammation + neuronal survival

naturally attract interest in diseases such as:

• Alzheimer’s disease
• Parkinson’s disease
• Dementia
• Other neurodegenerative disorders

But Semax is not an established treatment for any of them.

The connection is mostly:

mechanistic plausibility + preclinical research.

That’s enough to justify continued investigation.

It isn’t enough to claim disease modification.

What About Alzheimer’s Disease?

BDNF signaling is highly relevant to memory and neurodegenerative research.

So Semax often appears in Alzheimer’s discussions.

But no convincing large human clinical trial demonstrates that Semax:

prevents Alzheimer’s + slows Alzheimer’s progression + reverses dementia.

Those claims go considerably beyond the evidence.

What About Parkinson’s Disease?

Similar answer.

Neurotrophic and neuroprotective pathways are important in Parkinson’s research.

But Semax does not have a well-established human disease-modifying role in Parkinson’s disease.

Parkinson’s belongs as a research keyword, not an indication.

What About Migraine?

This is especially relevant because FDA specifically evaluated migraine as one of the proposed uses for Semax during its July 2026 Pharmacy Compounding Advisory Committee review. 

That does not mean FDA approved Semax for migraine.

Quite the opposite:

FDA’s review reflects that Semax was being considered as a bulk drug substance for compounding, and the agency evaluated whether evidence supported proposed uses including:

cerebral ischemia + migraine + trigeminal neuralgia.

FDA concluded that available clinical information was insufficient to adequately characterize Semax’s safety profile. 

So migraine is a legitimate research/search category.

It is not an FDA-approved indication.

What About Trigeminal Neuralgia?

Same situation.

FDA’s 2026 review specifically included trigeminal neuralgia among the proposed uses evaluated for Semax. 

But this was a compounding review, not drug approval.

Evidence remains inadequate to describe Semax as an established treatment for trigeminal neuralgia.

What About Anxiety?

Semax and Selank are frequently grouped together, which causes some confusion.

Selank

has a stronger research identity around:

anxiety + stress + GABAergic signaling.

Semax

has a stronger identity around:

neuroprotection + cognition + ischemia + BDNF/neurotrophic signaling.

Animal Semax research has sometimes found changes in anxiety-related behavior. 

But Semax doesn’t have the same human anxiety research history as Selank.

So if someone is specifically researching experimental anxiolytic peptides, Selank is generally the more directly relevant compound.

What About Depression?

BDNF and neuroplasticity are deeply involved in depression research.

That has led some people to frame Semax as an experimental antidepressant.

But Semax has not been established as a treatment for major depressive disorder.

The connection is primarily:

neurotrophic signaling + preclinical behavioral research.

So depression is a reasonable research area, not a proven therapeutic use.

What About Dopamine?

Semax is frequently marketed online as affecting:

dopamine + motivation + drive.

Neuropeptide and neurotransmitter interactions have been explored in experimental research, but the popular idea that Semax simply:

“raises dopamine”

is too crude.

Human studies have not established a predictable dopamine increase that translates into reliable improvements in:

motivation + ADHD + depression + productivity.

Use dopamine as a research keyword, not as a guaranteed mechanism/outcome claim.

What About Serotonin?

Same caution.

Semax can influence complex brain signaling and gene-expression systems.

But reducing the compound to:

“increases serotonin”

would misrepresent the research.

Its best-characterized scientific story remains neurotrophic and neuroprotective signaling rather than straightforward monoamine replacement.

What About NGF?

NGF stands for:

Nerve Growth Factor.

Like BDNF, it belongs to the neurotrophin family.

Animal research has found that Semax can affect NGF gene expression as well as BDNF.

A rat study demonstrated rapid changes in both BDNF and NGF expression after intranasal Semax administration. 

Another experimental ischemia study found Semax altered expression of NGF and multiple neurotrophin receptors after stroke-like injury. 

So neurotrophins beyond BDNF are part of the Semax story.

What About Oxidative Stress?

Ischemic and neurodegenerative injury often involves:

reactive oxygen species + mitochondrial dysfunction + oxidative damage.

Semax has been investigated in models involving these processes.

One interesting laboratory study also found Semax could bind copper ions and protect cultured cells from some metal-associated toxicity. 

That’s scientifically interesting.

It doesn’t mean Semax has been proven to:

detox heavy metals

or treat metal poisoning.

What About Inflammation?

Brain injury and ischemia trigger strong inflammatory responses.

Semax stroke research has investigated changes in inflammatory signaling.

An older clinical research report described shifts in post-ischemic inflammatory markers after Semax treatment. 

So:

neuroinflammation → legitimate area of study.

But Semax isn’t an established general anti-inflammatory medication.

Semax vs. Selank

This is worth making very clear because the two are constantly sold together.

Semax

Origin:

ACTH fragment

Research focus:

neuroprotection + cognition + ischemia + BDNF + NGF

Selank

Origin:

tuftsin-related peptide

Research focus:

anxiety + stress + GABA + neuroimmune signaling

Both:

• Are synthetic peptides
• Have Russian research histories
• Are frequently administered intranasally in published research
• Are marketed today as nootropics
• Remain unapproved by FDA

They’re related mostly by modern nootropic culture, not because they’re versions of the same molecule.

What About Semax + Selank Together?

This pairing is extremely common online.

The theory is usually:

Semax for cognition/focus + Selank for anxiety/calm.

That sounds neat.

But there isn’t strong controlled human evidence establishing that the combination provides:

synergy + better cognition + superior anxiety control + improved safety.

The compounds should be evaluated independently until combination research demonstrates otherwise.

What About N-Acetyl Semax Amidate?

Just as with modified Selank, research-market sellers offer modified versions of Semax.

Commonly encountered terms include:

N-Acetyl Semax Amidate

or:

NA-Semax Amidate.

These chemical modifications are generally intended to alter peptide stability and degradation.

But published studies of standard Semax cannot automatically be transferred to these modified analogues.

If the sequence changes, it is a different molecule.

Claims that modified Semax is:

stronger + more stable + longer lasting + more bioavailable

require direct comparative evidence.

We should treat those claims separately rather than calling every Semax analogue “Semax.”

Evidence Snapshot

Laboratory Research: Yes
Animal Research: Extensive
Human Clinical Research: Yes, but limited
Ischemic Stroke Research: Yes
Modern Large Stroke Trials: No
BDNF Research: Strong preclinical evidence
TrkB Research: Preclinical evidence
NGF Research: Preclinical evidence
Memory/Learning Research: Mainly animal evidence
Healthy-Person Nootropic Evidence: Limited
ADHD Evidence: Insufficient
Depression Evidence: Insufficient
Migraine Evidence: Insufficient for established treatment
Trigeminal Neuralgia Evidence: Insufficient
Human Pharmacokinetics: FDA reports no published human PK studies identified
FDA Approved: No
Overall Evidence: Legitimate and interesting neuroprotective research with limited human stroke experience, but considerably weaker clinical validation than its modern nootropic reputation implies. 

What Do We Know?

Semax isn’t an invented internet peptide.

We know exactly what it is:

Met-Glu-His-Phe-Pro-Gly-Pro.

There is substantial preclinical research showing effects involving:

BDNF + TrkB + NGF + neurotrophin gene expression + neurological injury responses.

And there is some human clinical experience, especially involving ischemic stroke. 

That’s considerably more evidence than exists for many online “brain peptides.”

What Don’t We Know?

We don’t have strong evidence proving Semax:

• Prevents stroke
• Reverses stroke damage
• Treats traumatic brain injury
• Treats concussion
• Prevents Alzheimer’s disease
• Treats Parkinson’s disease
• Treats dementia
• Treats ADHD
• Treats depression
• Treats anxiety disorders broadly
• Treats migraine
• Treats trigeminal neuralgia
• Eliminates brain fog
• Dramatically increases focus
• Increases intelligence
• Improves memory in healthy adults
• Reliably increases BDNF in humans
• Produces clinically meaningful neurogenesis in humans
• Permanently increases neuroplasticity
• Has an established human half-life
• Is safe for indefinite long-term use

That last group matters because Semax’s marketing tends to be much more confident than the clinical evidence.

What About Human Pharmacokinetics?

This is a surprisingly large evidence gap.

In its July 2026 review, FDA stated:

No published human pharmacokinetic studies of Semax were identified.

FDA also found:

• Insufficient information to characterize intranasal safety
• No safety data for the proposed subcutaneous route
• No published clinical immunogenicity studies identified

FDA additionally noted that one publication raised a possible concern about antithrombotic effects and bleeding risk, especially in susceptible populations or alongside medications that increase bleeding risk. 

That’s important because online sources often talk about Semax’s:

half-life + duration + ideal route

with much more certainty than the published human evidence supports.

What About Safety?

Older clinical literature has described Semax as generally well tolerated.

For example, a study involving cerebrovascular insufficiency reported relatively few adverse effects. 

But FDA’s much more recent 2026 assessment highlights how incomplete the safety database remains.

FDA states that compounded Semax may pose risks involving:

immunogenicity + peptide aggregation + peptide-related impurities.

And its July 2026 review concluded that available clinical information was insufficient to fully characterize safety. 

Both things can be true:

Older studies didn’t identify major obvious toxicity.

and:

Modern regulators still lack enough data to establish a robust safety profile.

Research & Regulatory Status

Semax is not FDA approved.

In July 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed:

Semax free base + Semax acetate

for proposed uses involving:

cerebral ischemia + migraine + trigeminal neuralgia.

That was a compounding evaluation, not approval of Semax as a drug.

FDA currently also identifies Semax among bulk substances that may present significant risks when compounded, specifically citing potential:

immunogenicity + aggregation + peptide-related impurities.

So the correct U.S. status is:

experimental / unapproved.

Semax’s historical use and research outside the United States should not be confused with FDA approval.

Your Pep Resource Takeaway

Semax is one of the more scientifically interesting “brain peptides.”

The basic story is legitimate:

ACTH fragment → Semax → animal neuroprotection studies → BDNF/TrkB and NGF research → limited human stroke research.

The BDNF connection is especially real.

Multiple animal studies show Semax can alter BDNF, TrkB, NGF, and related neurotrophic signaling.

And unlike many nootropic peptides, Semax actually has some human clinical research involving ischemic stroke. 

But modern marketing then takes that foundation and turns it into:

focus + ADHD + brain fog + depression + dopamine + memory + neuroplasticity + Alzheimer’s + concussion + brain optimization.

Most of those claims are far ahead of the clinical evidence.

And FDA’s 2026 review exposed an important reality:

We still don’t even have published human pharmacokinetic studies establishing basic questions such as Semax’s human exposure profile. 

So the best description isn’t:

“miracle nootropic.”

And it isn’t:

“fake research peptide.”

It’s:

A genuinely studied experimental neuroactive peptide with interesting neurotrophic and neuroprotective biology, some human stroke research, and major remaining gaps in modern clinical efficacy, pharmacokinetics, and safety data.

Research Areas / Search Keywords

Semax, Semax peptide, Semax acetate, ACTH peptide, ACTH fragment, ACTH 4-7, ACTH 4-10, ACTH(4-7)-Pro-Gly-Pro, ACTH(4-10) analogue, Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, Pro-Gly-Pro, PGP peptide, Russian peptide, Russian nootropic, nootropic, nootropic peptide, brain peptide, cognitive peptide, brain health, neurological health, neuroscience, cognition, cognitive function, cognitive performance, cognitive enhancement research, memory, memory research, memory problems, learning, learning research, focus, focus peptide, concentration, attention, attention research, ADHD research, executive function, mental clarity, brain fog, mental fatigue, productivity research, motivation research, BDNF, brain-derived neurotrophic factor, BDNF peptide research, TrkB, TrkB receptor, neurotrophins, neurotrophic factors, NGF, nerve growth factor, neuroplasticity, brain plasticity, synaptic plasticity, neurogenesis research, neuron survival, neuronal survival, neuroprotection, neuroprotective peptide, brain protection, brain recovery, stroke, ischemic stroke, cerebral ischemia, brain ischemia, stroke recovery, post-stroke recovery, stroke rehabilitation research, cerebral blood flow research, hypoxia, brain hypoxia, oxygen deprivation, ischemia reperfusion research, middle cerebral artery occlusion, MCAO, brain injury, traumatic brain injury, TBI research, concussion research, post-concussion research, neurological injury, neuroinflammation, brain inflammation, inflammation, oxidative stress, reactive oxygen species, ROS, antioxidant research, mitochondrial stress research, cerebrovascular disease, cerebrovascular insufficiency, transient ischemic attack research, TIA research, migraine, migraine research, headaches, chronic migraine research, trigeminal neuralgia, facial nerve pain research, nerve pain research, Alzheimer’s research, Alzheimer’s disease, dementia research, cognitive decline, age-related cognitive decline, Parkinson’s research, neurodegenerative disease, neurodegeneration, healthy brain aging, longevity brain research, depression research, low mood research, anxiety research, stress research, anxiety behavior, emotional regulation research, dopamine research, dopaminergic signaling, serotonin research, serotonergic signaling, neurotransmitters, neurotransmission, gene expression, neurological gene expression, BDNF gene expression, NGF gene expression, learning and memory, Semax BDNF, Semax focus, Semax memory, Semax stroke, Semax neuroprotection, Semax brain fog, Semax ADHD, Semax depression, Semax migraine, Semax vs Selank, Selank vs Semax, Semax and Selank, N-Acetyl Semax Amidate, NA Semax Amidate, N-Acetyl Semax, modified Semax, Semax analogue, intranasal peptide research, peptide nasal spray research, experimental brain peptides, research peptides.

---

Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, stroke treatment, psychiatric treatment, or purchasing recommendations. Semax is not FDA approved in the United States. Its strongest mechanistic evidence comes from laboratory and animal research, while human clinical evidence is limited and concentrated primarily in older studies involving cerebral ischemia. In 2026, FDA concluded that available information was insufficient to fully characterize Semax’s clinical safety and reported that it had not identified published human pharmacokinetic studies.